Catalioto, R.M., Maggi, C.A. and Giuliani, S. (2009) Chemically Distinct HDAC Inhibitors Prevent Adipose Conversion of Subcutaneous Human White Preadipocytes at an Early Stages of the Differentiation Program. Experimental Cell Research, 315, 3267-3280.
http://dx.doi.org/10.1016/j.yexcr.2009.09.012

has been cited by the following article:

• TITLE: Protein Lysine Acetylated/Deacetylated Enzymes and the Metabolism-Related Diseases

  AUTHORS: Qilin Wang, Shangjing Guo, Yaman Gao

  KEYWORDS: Lysine Acetylation, Acetyl CoA, Metabolism-Related Disease, Cardiovascular Disease, Obesity

  JOURNAL NAME: Advances in Bioscience and Biotechnology, Vol.7 No.11, November 18, 2016

  ABSTRACT: Lysine acetylation is a reversible posttranslational modifcation, an epigenetic phenomenon, referred to as transfer of an acetyl group from acetyl CoA to lysine ε- amino group of targeted protein, which is modulated by acetyltransferases (histone/ lysine (K) acetyltransferases, HATs/KATs) and deacetylases (histone/lysine (K) deacetylases, HDACs/KDACs). Lysine acetylation regulates various metabolic processes, such as fatty acid oxidation, Krebs cycle, oxidative phosphorylation, angiogenesis and so on. Thus disorders of lysine acetylation may be correlated with obesity, diabetes and cardiovascular disease, which are termed as the metabolic complication. With accumulating studies on proteomic acetylation, lysine acetylation also involves in cell immune status and degenerative diseases, for example, Alzheimer’s disease and Huntington’s disease. This review primarily summarizes the current studies of lysine acetylation in metabolism modulation and in metabolism-related diseases, such as cardiovascular disease and fat metabolism disorder.